|Bid||180.01 x 100|
|Ask||180.02 x 100|
|Day's Range||179.16 - 180.55|
|52 Week Range||133.64 - 184.21|
|PE Ratio (TTM)||17.12|
|Dividend & Yield||4.60 (2.57%)|
|1y Target Est||N/A|
Is Gilead Sciences (GILD) poised for a beat next week? Guggenheim analyst Tony Butler sees Gilead earning $2.15 a share, a penny above the consensus forecast compiled by sell-side analyst, with operating revenue of $6.54 billion beating the $6.31 billion expected by the Street. Butler’s estimates for the full 2017 calendar year are also above consensus, with per-share earnings of $8.28 on operating revenue of $25.4 billion.
While Amgen, Inc.'s (AMGN) growth drugs like Prolia & Xgeva might continue to do well. Biosimilar competition and slowdown in sales of mature products can put pressure on sales growth.
Amgen, Inc, Wal-Mart Stores, and Johnson & Johnson could provide safe havens during the next market crash.